Document is current
Any future updates will be listed below
-
Authors
Brahmer, Julie R
Abu-Sbeih, Hamzah
Ascierto, Paolo Antonio https://orcid.org/0000-0002-8322-475X
Brufsky, Jill
Cappelli, Laura C
Cortazar, Frank B
Gerber, David E
Hamad, Lamya
Hansen, Eric
Johnson, Douglas B
Lacouture, Mario E
Masters, Gregory A
Naidoo, Jarushka
Nanni, Michele
Perales, Miguel-Angel
Puzanov, Igor
Santomasso, Bianca D
Shanbhag, Satish P
Sharma, Rajeev
Skondra, Dimitra
Sosman, Jeffrey A
Turner, Michelle
Ernstoff, Marc S https://orcid.org/0000-0002-8132-7069
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04438382 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
https://doi.org/10.1136/jitc-2021-002435
Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540
Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
https://doi.org/10.1136/jitc-2020-002252
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-001884
Corticosteroid-resistant immune-related adverse events: a systematic review
https://doi.org/10.1136/jitc-2023-007409
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
https://doi.org/10.1136/jitc-2020-001731
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
https://doi.org/10.1136/jitc-2022-004670
- License Information
